Genome Vision: Financial Information for the First Quarter of 2022

  • Sales increased by + 72%

  • Business revenue increased by + 78%

  • € 1.3 million in cash as of March 31, 2022

Bagneux, France – (BUSINESS WIRE) – Regulatory News:

Genome vision (FR0011799907 – GV, PEA-PME target) (Paris: GV)A biotechnology company that develops tools and services dedicated to the analysis and control of genomic modifications, today announced one revenue.er Quarters as of March 31, 2022 and their cash.

Revenue from 1er 2022 quarter

Thousands of euros

First quarter of 2022

First quarter of 2021

Product sales

188

82

Service sales

96

83

Total trading volume

284

165

Other income / income

104

53

Total activity income

389

218

turn over From 1er In the 2022 quarter, it reached € 284,000, an increase of 72% compared to 1.er The 2021 quarter. This increase is primarily explained by the positive fundamental effects (the first quarter of 2021 was heavily affected by the Covid-19 crisis) and the one-year recovery.er The 2022 quarter of product sales and sales of service activities, especially due to efforts carried out in commercial exploration.

In connection with the health crisis that has had a significant impact on Genomic Vision’s activities and sales, the company has been conducting substantial and concrete research and development on targeted programs to enhance its commercial offering since 2021. I’ve been.

Total income from activities From 1er The 2022 quarter is up 78% compared to the first quarter, taking into account other revenues.er The 2021 quarter. Other revenues amounted to € 104,000, primarily equivalent to research tax credits, an increase compared to last year given the above focus.

Financial structure as of March 31, 2022

Genomic Vision’s cash was € 1.3 million as of March 31, 2022, compared to € 2.3 million as of December 31, 2021. Based on the planned development plan, the company estimates that it will be able to fund the activity to the end with the available cash. May 2022 (excluding possible exercise of BSA Winance and BSA Bracknor / Negma already in circulation), and the need for additional cash to be able to continue activities in 2022 is estimated at € 4 million It has been. To meet working capital needs:

  • The company has a financing line with Winance on June 11, 2020 by signing an OCABSA issuance agreement that has been used up to a total of 6 million euros (5.7 million euros after deduction) out of the possible 12 million euros. Decided to set. In any case, given the expiration of the prospectus associated with this business, which expired in June 2022, the company will not be able to use this funding line.

  • Through the signing of a new agreement signed on April 11, 2022, the company has decided to set up a new funding line with Winance, offering the company up to 15 tranches each of € 2 million. € 30 million, provided that the following conditions are met:

    • Get a visa from AMF with the new Prospectus,

    • Pre-approval of transactions by company shareholders at the extraordinary general meeting to be held on May 23, 2022

    • The drawing conditions of each tranche that should be respected, especially the market price, should not fall below the nominal value of the stock.

Not all are in the hands of the company If any or any of these preconditions do not materialize within a set time limit, the company realizes its assets and liabilities and the normal course of its business. The application of IFRS accounting rules and principles in the normal context of business continuity may prove inappropriate with respect to liabilities in, and especially in the valuation of assets and liabilities. As a result, this situation introduces significant uncertainty in operational continuity.

Future financial publications

  • Extraordinary General Meeting of Shareholders: Monday, May 23, 2022

  • Shareholders’ Meeting: Tuesday, June 28, 2022

  • Results for the first half of 2022: Thursday, September 29, 2022

  • 3 salesth Quarter 2022: Thursday, October 27, 2022

*** ***

About Genome Vision

GENOMIC VISION is a biotechnology company that develops products and services that specialize in the analysis of genomic modifications (structural and functional) and the control of the quality and safety of these modifications, especially in genomic editing and bioproduction processes. is. .. Based on DNA combing technology and artificial intelligence, GENOMICVISION’s unique tools provide the robust quantitative measurements needed for reliable characterization of DNA changes in the genome. These tools are used for early detection of cancer and diagnosis of genetic disorders, especially to monitor DNA replication in cancer cells. Based in Bagneux, Paris, the company has approximately 33 employees. GENOMIC VISION is listed on Compartment C (Euronext: GV – ISIN: FR0011799907), the regulated market for Euronext in Paris.

www.genomicvision.com

Index member CAC® Small and medium When CAC® All can be traded

caveat

This press release contains implicit or explicit forward-looking statements related to Genomic Vision and its activities. Genomic Vision believes that these forward-looking statements are based on reasonable assumptions. However, the forecasts shown in these forward-looking statements that are affected by risk, including those listed in the “Risk Factors” section of the Universal Registration Document registered with the Autorité des Financial Markets (Autorité des Financial Markets). We cannot guarantee achievement. AMF) Available on our website (www.genomicvision.com) on April 14, 2022, we are responding to changes in economic conditions, financial markets, and the markets in which GenomicVision resides. The forward-looking statements contained in this press release are also exposed to risks unknown to Genomic Vision or risks that Genomic Vision does not consider materiality at this time. Realizing all or part of these risks will result in the actual results, financial position, performance or outcomes of Genomic Vision differing significantly from the results, financial position, performance or performance shown in these forward-looking statements. There is a possibility.

This press release and the information contained therein do not constitute an offer or invitation to sell or subscribe to Genomic Vision shares, or an order or invitation to purchase or subscribe to Genomic Vision shares, and shall be construed in any country. It’s not a thing either. Distribution of this press release in certain countries may violate the legal provisions in force. Therefore, anyone in possession of a press release must notify themselves of regional restrictions and comply with them.

contact address

Genome vision
Dominique Remy-Lenou

Chairman of the Management Committee

like that. : +33 1 49 08 07 51

[email protected]

Ulysses Communication
Public relations

Bruno Arabian

like that. : +33 1 42 68 29 70

[email protected]

NewCap
Public relations activities for investors

& Strategic communication

like that. : +33 1 44 71 94 94

[email protected]